PKMYT1 | Protein kinase, membrane associated tyrosine/threonine 1 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
PLAC8 | Placenta-specific 8 | | | | | | Tissue enhanced |
PLAUR | Plasminogen activator, urokinase receptor | Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PLEK | Pleckstrin | Plasma proteins
| | | | | Tissue enhanced |
PLK4 | Polo-like kinase 4 | Enzymes
| | | | | Tissue enhanced |
PMAIP1 | Phorbol-12-myristate-13-acetate-induced protein 1 | Mitochondrial proteins
| | | | | Tissue enhanced |
POLQ | Polymerase (DNA directed), theta | Enzymes
| | | | | Tissue enhanced |
PROK2 | Prokineticin 2 | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
PSTPIP1 | Proline-serine-threonine phosphatase interacting protein 1 | Disease related genes
| | | | | Tissue enhanced |
PSTPIP2 | Proline-serine-threonine phosphatase interacting protein 2 | Cytoskeleton related proteins
| | | | | Tissue enhanced |
PTGER4 | Prostaglandin E receptor 4 (subtype EP4) | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
PTGS2 | Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | Cancer-related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
PTPN7 | Protein tyrosine phosphatase, non-receptor type 7 | Cytoskeleton related proteins Enzymes
| | | | | Tissue enhanced |
PTPRE | Protein tyrosine phosphatase, receptor type, E | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
PTX3 | Pentraxin 3, long | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
RASGRP4 | RAS guanyl releasing protein 4 | RAS pathway related proteins
| | | | | Tissue enhanced |
RELT | RELT tumor necrosis factor receptor | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
REM2 | RAS (RAD and GEM)-like GTP binding 2 | | | | | | Tissue enhanced |
RFESD | Rieske (Fe-S) domain containing | | | | | | Tissue enhanced |
RFX8 | RFX family member 8, lacking RFX DNA binding domain | Transcription factors
| | | | | Tissue enhanced |
RIPK2 | Receptor-interacting serine-threonine kinase 2 | Cytoskeleton related proteins Enzymes
| | | | | Tissue enhanced |
RNF182 | Ring finger protein 182 | Predicted membrane proteins
| | | | | Tissue enhanced |
RP11-212D19.4 | | | | | | | Tissue enhanced |
RP11-701P16.2 | Uncharacterized protein | | | | | | Tissue enhanced |
RP11-872D17.8 | Uncharacterized protein | Predicted membrane proteins
| | | | | Tissue enhanced |
RRM2 | Ribonucleotide reductase M2 | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
RUNX3 | Runt-related transcription factor 3 | Transcription factors
| | | | | Tissue enhanced |
S1PR5 | Sphingosine-1-phosphate receptor 5 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
SAMSN1 | SAM domain, SH3 domain and nuclear localization signals 1 | | | | | | Tissue enhanced |
SHCBP1 | SHC SH2-domain binding protein 1 | | | | | | Tissue enhanced |
SIGLEC5 | Sialic acid binding Ig-like lectin 5 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
SIGLEC5 | | Predicted membrane proteins
| | | | | Tissue enhanced |
SKA1 | Spindle and kinetochore associated complex subunit 1 | | | | | | Tissue enhanced |
SKA3 | Spindle and kinetochore associated complex subunit 3 | | | | | | Tissue enhanced |
SLC11A1 | Solute carrier family 11 (proton-coupled divalent metal ion transporter), member 1 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC22A15 | Solute carrier family 22, member 15 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC22A4 | Solute carrier family 22 (organic cation/zwitterion transporter), member 4 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC28A3 | Solute carrier family 28 (concentrative nucleoside transporter), member 3 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SMIM1 | Small integral membrane protein 1 (Vel blood group) | Blood group antigen proteins Predicted membrane proteins
| | | | | Tissue enhanced |
SNCA | Synuclein, alpha (non A4 component of amyloid precursor) | Cytoskeleton related proteins Disease related genes Plasma proteins Potential drug targets Transporters
| | | | | Tissue enhanced |
SPC24 | SPC24, NDC80 kinetochore complex component | | | | | | Tissue enhanced |
SPINK8 | Serine peptidase inhibitor, Kazal type 8 (putative) | Predicted secreted proteins
| | | | | Tissue enhanced |
SPN | Sialophorin | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
STK17B | Serine/threonine kinase 17b | Enzymes Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
STX11 | Syntaxin 11 | Disease related genes
| | | | | Tissue enhanced |
TAGAP | T-cell activation RhoGTPase activating protein | | | | | | Tissue enhanced |
TAL1 | T-cell acute lymphocytic leukemia 1 | Cancer-related genes Disease related genes Transcription factors
| | | | | Tissue enhanced |
TBX21 | T-box 21 | Disease related genes Transcription factors
| | | | | Tissue enhanced |
TMEM170B | Transmembrane protein 170B | Predicted membrane proteins
| | | | | Tissue enhanced |
TNF | Tumor necrosis factor | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins
| | | | | Tissue enhanced |